Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27743807 | 0.91 | DGAT1 (0.35) | DGAT1 | |
| SCHEMBL27360924 | 0.86 | DGAT1 (0.38) | DGAT1 | |
| SCHEMBL4366519 | 0.80 | DGAT1 (0.39) | DGAT1 | |
| SCHEMBL1066622 | 0.80 | DGAT1 (0.39) | DGAT1 | |
| SCHEMBL28721112 | 0.80 | DGAT1 (0.39) | DGAT1 | |
| SCHEMBL1422856 | 0.80 | DGAT1 (0.39) | DGAT1 | |
| SCHEMBL609386 | 0.80 | DGAT1 (0.39) | DGAT1 | |
| SCHEMBL29132474 | 0.80 | DGAT1 (0.39) | DGAT1 | |
| SCHEMBL3286466 | 0.80 | DGAT1 (0.39) | DGAT1 | |
| SCHEMBL4366521 | 0.80 | DGAT1 (0.39) | DGAT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4463445-B1 | COMPOUNDS AND USE THEREOF FOR THE TREATMENT OF DISEASES ASSOCIATED WITH IMPAIRED ?-GALACTOSIDASE ACTIVITY | DORPHAN S A (CH) | 2025-10-01 | — | — | EP | disclosed |
| US-20250073198-A1 | COMPOUNDS AND USE THEREOF FOR THE TREATMENT OF DISEASES ASSOCIATED WITH IMPAIRED ß-GALACTOSIDASE ACTIVITY | DORPHAN S.A. (CH) | 2025-03-06 | — | — | US | disclosed |
| EP-4463445-A1 | COMPOUNDS AND USE THEREOF FOR THE TREATMENT OF DISEASES ASSOCIATED WITH IMPAIRED ?-GALACTOSIDASE ACTIVITY | Dorphan S.A. (CH) | 2024-11-20 | — | — | EP | disclosed |
| WO-2023135480-A1 | COMPOUNDS AND USE THEREOF FOR THE TREATMENT OF DISEASES ASSOCIATED WITH IMPAIRED β-GALACTOSIDASE ACTIVITY | DORPHAN SA (CH) | 2023-07-20 | — | — | WO | disclosed |
| US-20180186860-A1 | SYNTHETIC APOLIPOPROTEINS, AND RELATED COMPOSITIONS METHODS AND SYSTEMS FOR NANOLIPOPROTEIN PARTICLES FORMATION | U.S. DEPARTMENT OF ENERGY | 2018-07-05 | — | — | US | disclosed |
| WO-2017044899-A1 | SYNTHETIC APOLIPOPROTEINS, AND RELATED COMPOSITIONS METHODS AND SYSTEMS FOR NANOLIPOPROTEIN PARTICLES FORMATION | LAWRENCE LIVERMORE NATIONAL SECURITY, LLC (US) | 2017-03-16 | — | — | WO | disclosed |
| EP-1866034-A1 | SUBSTITUTED 1,2-ETHYLENDIAMINES, MEDICAMENTS COMPRISING SAID COMPOUND; THEIR USE AND THEIR METHOD OF MANUFACTURE | Boehringer Ingelheim International GmbH (DE) | 2007-12-19 | — | — | EP | disclosed |
| WO-2006103038-A1 | SUBSTITUTED 1,2-ETHYLENDIAMINES, MEDICAMENTS COMPRISING SAID COMPOUND; THEIR USE AND THEIR METHOD OF MANUFACTURE | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2006-10-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250073198-A1 | COMPOUNDS AND USE THEREOF FOR THE TREATMENT OF DISEASES ASSOCIATED WITH IMPAIRED ß-GALACTOSIDASE ACTIVITY | MAN2B1, MANBA, GALC | DGAT1 776/4885AAK1 1637/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.